文献速递其他结缔组织病

线粒体移植作为特发性炎性肌病的新型治疗方法

Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy.
PubMed 文献 · Ann Rheum Dis · 2025-01-31

本研究通过体外和体内特发性炎性肌病(IIM)模型及首次人体1/2a期临床试验,评估人脐带间充质干细胞来源线粒体(PN-101)的疗效与安全性。PN-101可改善IIM成肌细胞线粒体功能与肌生成,在CIM小鼠中减轻肌炎严重程度;在9例难治性多发性肌炎或皮肌炎成人患者中未出现严重药物不良反应,IMACS-TIS较基线至少轻微改善。

要点

  • IIM患者成肌细胞存在线粒体功能与肌生成缺陷,PN-101可改善这些缺陷。
  • PN-101在CIM小鼠中通过抗炎和逆转代谢偏移减轻肌炎严重程度。
  • 1/2a期试验中9例难治性IIM患者未出现严重药物不良反应,IMACS-TIS较基线至少轻微改善。

核心结论

  • PN-101移植可能通过增强线粒体修复和减少肌肉组织炎症,成为IIM的一种新型治疗方法。

研究设计与样本

  • 研究采用体外和体内IIM模型,并开展首次人体1/2a期前瞻性临床试验,纳入9例难治性多发性肌炎或皮肌炎成人患者。
  • 体外模型使用IIM患者来源成肌细胞和经穿孔素/颗粒酶B处理的C2C12小鼠成肌细胞;体内模型使用C蛋白诱导性肌炎(CIM)小鼠。
  • 干预为从人脐带间充质干细胞分离的线粒体,命名为PN-101。

主要发现

  • IIM患者来源成肌细胞存在线粒体功能和肌生成缺陷,PN-101移植增强其肌肉分化和线粒体功能。
  • 在经穿孔素/颗粒酶B处理的C2C12成肌细胞中,PN-101提高细胞内三磷酸腺苷含量、细胞活力和肌生成。
  • 在CIM小鼠模型中,PN-101通过抗炎作用和恢复CIM诱导的代谢偏移减轻肌炎严重程度。
  • 在1/2a期临床试验中,PN-101未出现严重药物不良反应,与基线相比IMACS-TIS至少轻微改善。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to investigate the efficacy of mitochondrial transplantation as a therapeutic intervention for idiopathic inflammatory myopathy (IIM). This study used a comprehensive approach, incorporating both in vitro and in vivo IIM models, and conducted a first-in-human clinical trial to assess the effectiveness and safety of mitochondria isolated from human umbilical cord mesenchymal stem cells (PN-101). METHODS: Mitochondria isolated from umbilical cord mesenchymal stem cells were designated as PN-101. The efficacy of PN-101 was assessed using myoblasts derived from patients with IIM and C2C12 mouse perforin/granzyme B-treated myoblasts as an in vitro IIM model. PN-101's effect on IIM was examined using C protein-induced myositis (CIM) mice as an in vivo model. The efficacy and safety of PN-101 were evaluated in a phase 1/2a clinical trial involving 9 adult patients with refractory polymyositis or dermatomyositis. RESULTS: The myoblasts derived from patients with IIM exhibited defects in mitochondrial function and myogenesis. PN-101 transplantation enhances muscle differentiation and mitochondrial function in IIM myoblasts. PN-101 also enhanced intracellular adenosine triphosphate content, cell viability, and myogenesis in C2C12 perforin/granzyme B-treated myoblasts. In an in vivo model, PN-101 reduced myositis severity by exhibiting anti-inflammatory effects and restoring the CIM-induced metabolic shift. In a phase 1/2a prospective clinical trial involving adult patients with refractory IIM, PN-101 demonstrated no severe adverse drug reactions and showed at least minimal improvement in the International Myositis Assessment and Clinical Studies Group (IMACS)-Total Improvement Scores (TISs) compared with baseline. CONCLUSIONS: PN-101 transplantation could serve as a novel treatment for IIM by enhancing mitochondrial repair and reducing inflammation in muscle tissues.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kim JY, Kang YC, Kim MJ, et al. Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy. Ann Rheum Dis. 2025. PMID: 39893098. doi:10.1016/j.ard.2024.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。